Mathieu Bourdenx

List of Publications by Year
in descending order

39 papers	4,307 citations	257101 24 h-index	315357 38 g-index
45 all docs	45 docs citations	45 times ranked	6865 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 742 Td	4.3	1,430
2	Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	4.9	393
3	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	2.8	379
4	Selective autophagy as a potential therapeutic target for neurodegenerative disorders. Lancet Neurology, The, 2018, 17, 802-815.	4.9	269
5	Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell, 2021, 184, 2696-2714.e25.	13.5	151
6	The different autophagy degradation pathways and neurodegeneration. Neuron, 2022, 110, 935-966.	3.8	150
7	Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy, 2016, 12, 472-483.	4.3	146
8	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193.	2.8	137
9	Proteome-wide analysis of chaperone-mediated autophagy targeting motifs. PLoS Biology, 2019, 17, e3000301.	2.6	136
10	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain, 2020, 143, 1462-1475.	3.7	135
11	Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. Frontiers in Neuroscience, 2017, 11, 26.	1.4	110
12	Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nature Communications, 2021, 12, 2238.	5.8	101
13	In vitro Î±-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiology of Disease, 2017, 103, 101-112.	2.1	96
14	Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by Î±-synuclein overexpression. Acta Neuropathologica Communications, 2015, 3, 46.	2.4	88
15	Lysosomes and ÃŽÂ±-synuclein form a dangerous duet leading to neuronal cell death. Frontiers in Neuroanatomy, 2014, 8, 83.	0.9	76
16	Selective Inactivation of Striatal FosB/Î”FosB-Expressing Neurons Alleviates L-DOPAâ€“Induced Dyskinesia. Biological Psychiatry, 2016, 79, 354-361.	0.7	68
17	Systemic gene delivery to the central nervous system using Adeno-associated virus. Frontiers in Molecular Neuroscience, 2014, 7, 50.	1.4	65
18	Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. JCI Insight, 2019, 4, .	2.3	54

#	Article	IF	Citations
19	Targeting Î±â€synuclein: Therapeutic options. Movement Disorders, 2016, 31, 882-888.	2.2	37
20	Identification of distinct pathological signatures induced by patient-derived Î±-synuclein structures in nonhuman primates. Science Advances, 2020, 6, eaaz9165.	4.7	34
21	Reciprocal regulation of chaperone-mediated autophagy and the circadian clock. Nature Cell Biology, 2021, 23, 1255-1270.	4.6	33
22	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. Acta Neuropathologica, 2019, 137, 71-88.	3.9	29
23	Protective role of chaperone-mediated autophagy against atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2121133119.	3.3	29
24	Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease, 2014, 62, 307-312.	2.1	25
25	Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model. Scientific Reports, 2017, 7, 45831.	1.6	21
26	Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy, 2021, 17, 2040-2042.	4.3	21
27	What lysosomes actually tell us about Parkinsonâ€™s disease?. Ageing Research Reviews, 2016, 32, 140-149.	5.0	19
28	CB1-receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination. ELife, 2020, 9, .	2.8	19
29	Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain, 2022, 145, 1001-1017.	3.7	14
30	D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly. Neurobiology of Disease, 2015, 78, 77-87.	2.1	10
31	In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinsonâ€™s disease. Gene Therapy, 2017, 24, 801-809.	2.3	8
32	Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. Scientific Reports, 2017, 7, 2348.	1.6	6
33	Down-regulating Î±-synuclein for treating synucleopathies. Movement Disorders, 2014, 29, 1463-1465.	2.2	4
34	Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkey. Synapse, 2016, 70, 52-56.	0.6	3
35	DNA as the next digital information storage support. Movement Disorders, 2013, 28, 583-583.	2.2	1
36	Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats. Human Gene Therapy Methods, 2018, 29, 189-199.	2.1	1

#	Article	IF	Citations
37	Phosphorylation of Î±-Synuclein at ser120 accelerates neurodegeneration. Movement Disorders, 2013, 28, 441-441.	2.2	0
38	Allograft of stem cellâ€derived dopaminergic neurons for Parkinson's disease. Movement Disorders, 2013, 28, 736-736.	2.2	0
39	Alphaâ€synuclein inoculation initiates a neurodegenerative cascade in nontransgenic mice. Movement Disorders, 2013, 28, 126-126.	2.2	0